Bionexus Gene Lab vs Seer
Seer is the larger business, with $16.6m of revenue in fiscal 2025 against $7.4m for Bionexus Gene Lab (2.2 times as much). Seer grew faster (17.0% against -21.9%). Bionexus Gene Lab kept more of each dollar of sales as profit: a net margin of -40.2% against -444.0%.
| Latest fiscal year | Bionexus Gene LabBGLC, 2025 | SeerSEER, 2025 |
|---|---|---|
| Revenue | $7.4m | $16.6m |
| Revenue growth | -21.9% | 17.0% |
| Net income | −$3.0m | −$73.6m |
| Operating margin | — | -470.5% |
| Net margin | -40.2% | -444.0% |
| Return on equity | -35.2% | -25.1% |
| Free cash flow | −$1.9m | −$46.2m |
| Cash | $2.4m | $47.3m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $2.3m | $94.7m |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | 22 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 7 sales |